Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients

Trial Profile

A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amoxicillin/omeprazole/rifabutin (Primary)
  • Indications Helicobacter pylori infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ERADICATE-Hp
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 28 Oct 2020 Results assessing effectiveness of PD therapy for persistent H. pylori infection from trials ERADICATE Hp & ERADICATE Hp2 presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020
    • 28 Oct 2020 Results of post hoc pooled analysis from two phase 3 trials (NCT01980095 & NCT03198507) presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020
    • 26 Oct 2020 According to an RedHill Biopharma media release, post hoc analysis from this trial will be presented at the American College of Gastroenterology (ACG) 2020 Virtual Annual Scientific Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top